LLY•benzinga•
Sangamo Therapeutics Enters Capsid License Agreement With Lilly; To Receive $18M Upfront License Fee And Is Eligible To Earn Up To $1.4B In Additional Licensed Target Fees And Milestone Payments
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga